首页> 外文期刊>Chinese Medicine >A network pharmacology-based strategy deciphers the underlying molecular mechanisms of Qixuehe Capsule in the treatment of menstrual disorders
【24h】

A network pharmacology-based strategy deciphers the underlying molecular mechanisms of Qixuehe Capsule in the treatment of menstrual disorders

机译:基于网络药理学的策略解释了气血合胶囊治疗月经失调的潜在分子机制

获取原文
           

摘要

Background QiXueHe Capsule (QXHC) is a Chinese patent drug that is extensively used for the treatment of menstrual disorders. However, its underlying pharmacological mechanisms have not been fully elucidated. Methods A list of QXHC putative targets were predicted using MetaDrug. An interaction network using links between QXHC putative targets and the known therapeutic targets of menstrual disorders was constructed. QXHC candidate targets were also identified via calculating the topological feature values of nodes in the network. Additionally, molecular docking simulation was performed to determine the binding efficiency of QXHC compound-putative target pairs. Results A total of 1022 putative targets were predicted for 311 chemical components containing in QXHC. Following the calculation of topological features of QXHC putative target-known therapeutic target of menstrual disorder network, 66 QXHC candidate targets for the treatment of menstrual disorders were identified. Functionally, QXHC candidate targets were significantly associated with several biological pathways, such as VEGF and Chemokine signaling pathways, Alanine/aspartate/glutamate metabolism, Long-term depression and T/B cell receptor signaling pathway. Moreover, molecular docking simulation demonstrated that there were 20 pairs of QXHC chemical component-candidate target had the strong binding free energy. Conclusions This novel and scientific network pharmacology-based study holistically deciphers that the pharmacological mechanisms of QXHC in the treatment of menstrual disorders may be associated with its involvement into hemopoiesis, analgesia, nutrients absorption and metabolism, mood regulation, as well as immune modulation.
机译:背景气血合胶囊(QXHC)是一种中国专利药物,被广泛用于治疗月经失调。但是,其潜在的药理机制尚未完全阐明。方法使用MetaDrug预测QXHC推定目标的清单。利用QXHC推定目标与月经失调的已知治疗目标之间的联系构建了一个相互作用网络。还可以通过计算网络中节点的拓扑特征值来识别QXHC候选目标。此外,进行分子对接模拟以确定QXHC化合物与靶标对的结合效率。结果预测了QXHC中包含的311种化学成分的总共1022个目标。通过计算QXHC推定目标的已知拓扑结构(月经网络的已知治疗目标)的拓扑特征,确定了66个用于治疗月经紊乱的QXHC候选目标。在功能上,QXHC候选靶标与多种生物学途径显着相关,例如VEGF和趋化因子信号通路,丙氨酸/天冬氨酸/谷氨酸代谢,长期抑郁和T / B细胞受体信号通路。此外,分子对接模拟表明有20对QXHC化学成分候选目标具有很强的结合自由能。结论这项新颖,科学的基于网络药理学的研究从整体上解释了QXHC治疗月经紊乱的药理机制可能与其参与造血,止痛,营养吸收和代谢,情绪调节以及免疫调节有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号